Halozyme Therapeutics, Inc. (NASDAQ: HALO)

Halozyme Therapeutics, Inc. is a biopharmaceutical company focused on drug delivery technologies that enable subcutaneous administration of therapeutics. Its core technology is ENHANZE, which uses recombinant human hyaluronidase to improve dispersion and absorption of injected drugs. The company also develops Hypercon and Surf Bio platforms for high concentration formulations and provides auto‑injector devices for self‑administration. It partners with large pharma companies to co‑develop and commercialize combination products.

The company earns revenue from upfront licensing fees, milestone payments, sales of bulk rHuPH20, and royalties on commercial sales of partner products that incorporate its ENHANZE, Hypercon or Surf Bio technologies. It also generates sales from its own marketed products, Hylenex recombinant and XYOSTED, and from supplying drug‑device combination products such as auto‑injectors to partners like Teva.

Halozyme holds a leading position in the subcutaneous drug delivery market, competing with other enzyme‑based platforms such as Alteogen’s ALT‑B4 and various microneedle or high‑concentration technologies. Its competitive advantage lies in the broad patent portfolio covering rHuPH20, Hypercon and Surf Bio, extensive collaborations with top pharmaceutical firms, and regulatory approvals for multiple marketed products.

The company serves biopharmaceutical partners including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol‑Myers Squibb, argenx, ViiV Healthcare, Chugai, Acumen, Merus and Skye Bioscience, as well as end‑users of its own products such as hospitals, clinics and patients receiving Hylenex or XYOSTED therapy.